Skip to main content
. 2021 Dec 20;23(2):54. doi: 10.3892/ol.2021.13172

Figure 2.

Figure 2.

Differential expression of HSD11B1-AS1 and its association with patient clinicopathological characteristics. (A) Significantly decreased HSD11B1-AS1 levels were demonstrated in cutaneous melanoma compared with healthy tissues. (B) Receiver operating characteristic curve of HSD11B1-AS1 predicting a good diagnostic performance in discriminating melanoma from healthy tissues. (C) HSD11B1-AS1 expression levels were assessed in various types of human cancer. Decreased expression of HSD11B1-AS1 was significantly associated with advanced (D) T stage, (E) Clark levels, (F) pathological stage, (G) Breslow depth and (H) melanoma ulceration. *P<0.05, **P<0.01 and ***P<0.001. HSD11B1-AS1, 11β-hydroxysteroid dehydrogenase type 1-antisense RNA 1; AUC, area under the curve; CI, confidence interval; TCGA, The Cancer Genome Atlas; GSEA, Gene Set Enrichment Analysis; TPM, transcripts per million; TPR, true positive rate; FPR, false positive rate.